Nathaniel R. McLauchlan

Nathaniel R. McLauchlan

Auto-generated profile, based on publicly available information

Nathaniel R. McLauchlan

Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2023 in Trauma Surgery & Acute Care Open
Verified
Journal Article
Open access
PDF file
NMNathaniel R McLauchlan
Nathaniel R McLauchlan
NINoah M Igra
Noah M Igra
LFLydia T Fisher
Lydia T Fisher
JBJames P Byrne
James P Byrne
CBCarl A Beyer
Carl A Beyer
JCJeremy W Cannon
Jeremy W Cannon
Objective To quantify and assess the relative performance parameters of thoracic lavage and percutaneous thoracostomy (PT) using a novel, basic science 2×2 randomized controlled simulation trial. Summary background data Treatment of traumatic hemothorax (HTX) with open tube thoracostomy (TT) is painful and retained HTX is common. PT is potentially less painful whereas thoracic lavage may reduce retained HTX. Yet, procedural time and the feasibility of combining PT with lavage remain undefined. Methods A simulated partially clotted HTX (2%-gelatin-saline mixture) was loaded into a TT trainer and then evacuated after randomization to one of four protocols: TT+/-lavage or PT+/-lavage. Standardized inserts with fixed 28-Fr TT or 14-Fr PT positioning were used to minimize tube positioning variability. Lavage consisted of two 500 mL aliquots of warm saline after initial HTX evacuation. The primary outcome was HTX volume evacuated. The secondary outcome was additional procedural time required for the addition of the lavage. Results A total of 40 simulated HTX trials were randomized. TT alone evacuated a median of 1236 mL (IQR 1168, 1294) leaving a residual volume of 265 mL (IQR 206, 333). PT alone resulted in a significantly greater median residual volume of 588 mL (IQR 497, 646) (p=0.002). Adding lavage resulted in similar residual volumes for TT compared with TT alone but significantly less for PT compared with PT alone (p=0.002). Lavage increased procedural time for TT by a median of 7.0 min (IQR 6.5, 8.0) vs 11.7 min (IQR 10.2, 12.0) for PT (p<0.001). Conclusion This simulation trial characterized HTX evacuation in a standardized fashion. Adding lavage to thoracostomy placement may improve evacuation, particularly for small-diameter tubes, with little added procedural time. Further prospective clinical study is warranted. Level of evidence NA.

12 August 2024 in Journal of Surgical Education
Verified
Journal Article
Closed access
NMNathaniel R. McLauchlan
Nathaniel R. McLauchlan
LFLane L. Frasier
Lane L. Frasier
LFLydia Fisher
Lydia Fisher
JCJennifer Carroll
Jennifer Carroll
CCCindy W. Christian
Cindy W. Christian
JCJeremy W. Cannon
Jeremy W. Cannon

27 July 2024 in Transfusion
Verified
Journal Article
Open access
DSDaniela Schmulevich
Daniela Schmulevich
ZGZhi Geng
Zhi Geng
SJSarah M. Joergensen
Sarah M. Joergensen
NMNathaniel R. McLauchlan
Nathaniel R. McLauchlan
EWEric Winter
Eric Winter
JCJeremy W. Cannon
Jeremy W. Cannon
Background: Maintaining balanced blood product ratios during damage control resuscitation (DCR) is independently associated with improved survival. We hypothesized that real‐time performance improvement (RT‐PI) would increase adherence to DCR best practice.Study Design and Methods: From December 2020–August 2021, we prospectively used a bedside RT‐PI tool to guide DCR in severely injured patients surviving at least 30 min. RT‐PI study patients were compared to contemporary control patients at our institution and historic PROMMTT study patients. A subset of patients transfused ≥6 U red blood cells (RBC) in 6 h (MT+) was also identified. The primary endpoint was percentage time in a high ratio range (≥3:4) of plasma (PLAS):RBC and platelet (PLT):RBC over 6 h. Secondary endpoints included time to massive transfusion protocol activation, time to calcium and tranexamic acid (TXA) dosing, and cumulative 6‐h ratios.Results: Included patients (n = 772) were 35 (24–51) years old with an Injury Severity Score of 27 (17–38) and 42% had penetrating injuries. RT‐PI (n = 10) patients spent 96% of the 6‐h resuscitation in a high PLAS:RBC range, no different versus CONTROL (n = 87) (96%) but more than PROMMTT (n = 675) (25%, p < .001). In the MT+ subgroup, optimal PLAS:RBC and PLT:RBC were maintained for the entire 6 h in RT‐PI (n = 4) versus PROMMTT (n = 391) patients for both PLAS (p < .001) and PLT ratios (p < .001). Time to TXA also improved significantly in RT‐PI versus CONTROL patients (27 min [22–31] vs. 51 min [29–98], p = .035).Conclusion: In this prospective study, RT‐PI was associated with optimized DCR. Multicenter validation of this novel approach to optimizing DCR implementation is warranted.

1 May 2024 in Urology Practice
Verified
Journal Article
Closed access
IHI. Mitchell Harmatz
I. Mitchell Harmatz
KAKhalid Y. Alkhatib
Khalid Y. Alkhatib
MLMorgan Leff
Morgan Leff
JNJosé Ignacio Nolazco
José Ignacio Nolazco
KMKatharine F. Michel
Katharine F. Michel
PPPhillip M. Pierorazio
Phillip M. Pierorazio
Cigarette smoking is associated with higher-risk prostate cancer at the time of diagnosis and increased overall and prostate cancer‒specific mortality. Previous studies indicate smokers are less likely to undergo PSA screening. Herein we investigate the association between smoking and PSA screening using a nationally representative US survey. We hypothesize that smokers are less likely to undergo guideline-concordant PSA screening. We performed a cross-sectional analysis of men aged 55 to 69 who responded to the cigarette smoking and PSA screening questions of the 2018 Behavioral Risk Factor Surveillance System survey. Adjusted prevalence and adjusted risk differences were calculated using complex weighted multivariable Poisson regression modeling. We identified 58,996 individuals who qualified for analysis. PSA screening prevalence was 39% (95% CI: 39%-40%) nationally, 42% (95% CI: 41%-44%) for never smokers, 42% (95% CI: 39%-40%) for former smokers, and 27% (95% CI: 25%-29%) for current smokers, including 27% (95% CI: 24%-29%) for daily smokers and 29% (95% CI: 24%-33%) for nondaily smokers. Compared to never smokers, the adjusted relative risk for undergoing PSA screening was 0.81 for current smokers (95% CI: 0.75-0.88, P < .01) and 0.99 for former smokers (95% CI: 0.94-1.03, P = .53). Current smokers are less likely to undergo recommended PSA screening, but former smokers are screened at similar rates as never smokers. As delays in diagnosis may substantially contribute to worse prostate cancer outcomes, targeted interventions to increase screening in this population may yield significant effects.

1 May 2024 in Urology Practice
Verified
Journal Article
Closed access
IHI. Mitchell Harmatz
I. Mitchell Harmatz
KAKhalid Y. Alkhatib
Khalid Y. Alkhatib
MLMorgan Leff
Morgan Leff
JNJosé Ignacio Nolazco
José Ignacio Nolazco
KMKatharine F. Michel
Katharine F. Michel
PPPhillip M. Pierorazio
Phillip M. Pierorazio